The FDA has approved Noctiva (desmopressin acetate) nasal spray for frequent urination at night in adults due to overproduction of urine.
Indications: Noctiva is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.
Dosage/administration: Prime with 5 actuations before initial use if not use for more than 3 days.
- For patients aged <65 years who are not at increased risk for hyponatremia: Use 1 spray of 1.66 mcg in either nostril nightly approximately 30 minutes before going to bed.
- For patients ≥65 years or younger patients at risk for hyponatremia: Use 0.83 mcg nightly, which can be increased to one spray of 1.66 mcg after at least 7 days, if needed, provided the serum sodium has remained normal.
Adverse reactions: Common adverse reactions in clinical trials (incidence >2%) included nasal discomfort, nasopharyngitis, nasal congestion, sneezing, hypertension/blood pressure increased, back pain, epistaxis, bronchitis and dizziness.
US Food and Drug Administration. FDA approves first treatment for frequent urination at night due to overproduction of urine. FDA Web site. March 3, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm544877.htm. Accessed March 10, 2017.
This Week's Must Reads
AHA/ACC Issues New Hypertension Guideline, Hypertension; ePub 2017 Nov 13; Whelton, et al
Sustainability of Diabetes Prevention Strategies, JAMA Intern Med; ePub 2017 Nov 6; Haw, et al
Trends in Antidiabetes Drug Usage in US, Diabetes Care; ePub 2017 Nov 6; Montvida, et al
Opioid vs Nonopioid Pain Reduction in the ED, JAMA; 2017 Nov 7; Chang, Bijur, et al
Self-Administered Treatment for Latent Tuberculosis, Ann Intern Med; ePub 2017 Nov 7; Belknap, et al
Must Reads in FDA Actions
Shingrix Approved for Prevention of Shingles, GSK news release; 2017 Oct 23
FDA Approves Fast-Acting Mealtime Insulin, Novo Nordisk news release; 2017 Sep 29
FDA Approves FreeStyle Libre System for Adults, FDA news release; 2017 Sep 27
FDA Approves Single Inhaler Triple COPD Therapy, GSK news release; 2017 Sep 18
FDA OKs Diabetes Drug Indication to Reduce CV Risk, Novo Nordisk news release; 2017 Aug 25